Johnson and Johnson Rybrevant Faspro Gets USFDA Accelerated Approval for Advanced Head, Neck Cancer

Coverage, in order

1. 5d ago
   
   Medical Dialogues India obscure

   Johnson and Johnson Rybrevant Faspro Gets USFDA Accelerated Approval for Advanced Head, Neck Cancer

   Bengaluru : The US Food and Drug Administration on Thursday granted accelerated approval to Johnson & Johnson's treatment for patients with an advanced form of head and neck cancer whose disease has worsened after chemotherapy and immunotherapy. The drug, Rybrevant Faspro, is approved for patients…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.